药物基因组学在儿科中的现实应用
Christopher N Newbound1, Bradley Roberts2,3, Zahra Cooper2
1Gene S Pty Ltd, Nedlands, Australia.
Journal of paediatrics and child health
|December 13, 2025
概括
药物基因组学 (PGx) 测试指导儿童个性化医疗,提高药物安全性和有效性,特别是在瘤学和精神病学中. 克服实施障碍是更广泛临床使用的关键.
科学领域:
- 药物基因组学 药物基因组学
- 儿科药理学 儿科药理学
- 临床遗传学 临床遗传学
背景情况:
- 药物基因组学 (PGx) 研究影响药物反应的遗传变异.
- 临床PGx测试优化了个性化药物治疗,减少了药物不良反应并提高了治疗结果.
- 本综述侧重于PGx在儿科的应用,特别是瘤学,精神病学和支持性护理.
研究的目的:
- 审查在儿科群体中药物基因组学测试的临床应用.
- 突出PGx在儿科瘤学,精神病学,炎症性肠病和其他领域的实用性.
- 确定PGx实施的障碍,并提出未来的方向.
主要方法:
- 在儿科临床药物基因组学应用的文献综述.
- 分析表明量身定制药物治疗影响的案例研究.
- 讨论影响PGx采用的系统,教育和经济因素.
主要成果:
- 在儿科瘤学中,PGx引导的治疗,如TPMT和NUDT15,在不影响复发率的情况下降低了毒性.
- 在炎症性肠道疾病,抗菌药物管理,止痛和精神药物处方中证明了临床效用.
- 系统性障碍包括临床医生的培训有限,报告复杂,公众意识低,以及访问和报销问题.
结论:
- 药物基因组学对通过个性化医学改善儿科患者护理具有重大前景.
- 通过标准化报告,教育和协作解决实施障碍对于更广泛的采用至关重要.
- 持续的研究,年龄特定的指导方针和经济分析对于推进儿科药物基因组学至关重要.
更多相关视频
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
1.3K
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.5K
相关概念视频
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
174
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
174
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
194
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
194
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
229
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
229
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
240
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
240
01:12Analysis of Population Pharmacokinetic Data
653
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
653
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
133
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
133